Because its high tumor specificity compared to other TNF family members, recombinant TRAIL, TRAIL receptor agonists and other therapeutic agents had been studied for cancer therapies by activating TRAIL pathway to induce tumor-selective apoptosis (Singh et al., 2021; von Karstedt et al., 2017; Yuan et al., 2018). Here, TNFSF10 is linked to cancer.